PRRT2 and myeloid sarcoma: Although the Sph toxicity as an inhibitor of PKC has been established [14], its role in neurological disorder has not been reported until a recent report from our laboratories indicating Sph toxicity in degeneration of oligodendrocytes and neurons in MS demyelination [15].